rs7495132

This is a intron variant variant in the CRTC3 gene.

GWAS Catalog Trait Associations (2)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

inflammatory bowel disease

Allele C
OR 1.13
p 9.0e-11
N 34,366
Large GWAS
European

colorectal cancer

Allele T
OR 1.11
p 8.0e-10
N 92,967
Large GWAS
European

Research that mentions this SNP (1)

The CDH1‐160C&gt;A polymorphism is a risk factor for colorectal cancer
AssociationN=1,926Alan M. Pittman et al.(2009)· International Journal of Cancer

This study examined the relationship between 233 colorectal cancer (CRC) risk loci and overall survival in 1,926 patients with advanced CRC from clinical trials. Two SNPs significantly associated with survival under a recessive model were identified: rs117079142 (HR=2.79, 95% CI=1.70-4.58, P=4.7×10⁻⁵) mapping to UTP23/EIF3H, and rs9924886 (HR=1.24, 95% CI=1.12-1.38, P=5.2×10⁻⁵) mapping to CDH1/CDH3. Low CDH1 gene expression in tumors was associated with worse survival (HR=2.18, P=1.8×10⁻³), supporting a prognostic role for CDH1 variants.

Traits studied:Colorectal cancerColorectal cancer prognosisOverall survival in advanced colorectal cancer

About CRTC3

This gene is a member of the CREB regulated transcription coactivator gene family. This family regulates CREB-dependent gene transcription in a phosphorylation-independent manner and may be selective for cAMP-responsive genes. The protein encoded by this gene may induce mitochondrial biogenesis and attenuate catecholamine signaling in adipose tissue. A translocation event between this gene and Notch coactivator mastermind-like gene 2, which results in a fusion protein, has been reported in mucoepidermoid carcinomas. Alternative splicing results in multiple transcript variants that encode different protein isoforms. [provided by RefSeq, Jul 2012]

View all CRTC3 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…